Category Archives: Clinician Engagement

ADAPTABLE Study Welcomes HealthCore and LHSNet Networks to the Team

The National Patient-Centered Clinical Research Network (PCORnet) demonstration study, ADAPTABLE, welcomes two new partners as participating networks: HealthCore-Anthem Research Network and Patient-Centered Network of Learning Health Systems (LHSNet).

HealthCore, a subsidiary of Anthem, is a health plan research network with 140 highly specialized, multi-disciplinary professionals dedicated to health services and outcomes research. Through Anthem, HealthCore has access to approximately 60 million individuals from across the United States. HealthCore began its initial outreach to 135,000 eligible patients covered by Anthem, and in less than a month more than 400 eligible patients have visited the ADAPTABLE patient portal and 104 of them have already enrolled. The addition of HealthCore as an enrolling site for ADAPTABLE creates a novel partnership where health plan claims data are contributing to the primary data collected in this clinical study.

LHSNet is a diverse network of health institutions across the mid-west and mountain states that collectively serve approximately 10 million patients including underserved and rural areas. Similar to HealthCore and other participating networks in ADAPTABLE, the six LHSNet sites will use a computable phenotype, an electronic formula within the health record system, to identify eligible patients at each of the participating locations.

Highlighting the collaborative nature of PCORnet, LHSNet leadership is actively incorporating best practices from currently enrolling sites to optimize clinician engagement, patient engagement, and recruitment strategies. “The collaborative environment between the site teams to work together and learn how to successfully manage a large pragmatic clinical study is something I have never witnessed on any other large clinical trial,” said Project Leader Holly Robertson, PhD. “It is definitely a unique experience and it is really exciting to be a part of such a novel study.”

The addition of these networks allows for the expansion of ADAPTABLE to new geographical areas and will help to support the goal of enrolling up to 15,000 patients to answer a simple but critical question that is important to individuals living with heart disease and their providers: What is the most effective dose (81mg or 325mg) of aspirin for patients with cardiovascular disease? “The ADAPTABLE demonstration study within PCORnet continues to break new ground with innovative ways to engage patients and clinicians in important, pragmatic clinical research, as demonstrated by the inclusion of HealthCore and LHSNet,” says ADAPTABLE Co-Principal Investigator Schuyler Jones, MD.

Facebook Live Broadcast: What is the Optimal Dose of Aspirin for Patients with Heart Disease?

In conjunction with The American Heart Association  2016 Scientific Sessions and REACHnet CDRN Health in Our Hands Network,  ADAPTABLE will be live on Facebook on November 15 at 10:15 CST. Co-Principal Investigator, Dr. Matthew Roe, and patient participant, Ken Grigoire, will answer your questions about ADAPTABLE, a study that seeks to understand what is the optimal dose of aspirin for patients with heart disease.

facebook-live-broadcast

The ADAPTABLE study is being presented to fellow clinicians, researchers and scientists attending Scientific Sessions, Nov. 12th – Nov 16th in New Orleans. #AHA16 is the leading cardiovascular meeting in the country with more than 17,000 professionals attending annually. The scientific programming is designed to improve patient care by providing a forum for researchers and scientists to share significant advances in prevention, diagnosis and treatment of cardiovascular disease from different perspectives. www.scientificsessions.org.

Join us on November 15 at 10:15 CST for the LIVE Q&A by visiting: www.facebook.com/events/363697957306812/

 

ADAPTABLE Study Kick-Off Meeting: Determining the Path Forward for ADAPTABLE and Pragmatic Research

Patient engagement and patient-centricity are hot topics in clinical research and study teams are trying creative approaches to involve patients in the research process. These teams can look to the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial as an emerging model for patient engagement in randomized trials. Patient leaders, study investigators, and operations and research staff gathered together on October 28, 2016 in Washington D.C. to discuss ideas and strategies for making this novel, pragmatic study a success.
adapt-study

Continue reading ADAPTABLE Study Kick-Off Meeting: Determining the Path Forward for ADAPTABLE and Pragmatic Research

The Role and Importance of the Clinician in ADAPTABLE

In this feature of Ask ADAPTABLE, Dr. Schuyler Jones, an investigator with the Duke Clinical Research Institute Coordinating Center, discusses the role and importance of the clinician in the ADAPTABLE study.

Q: What is the role of the clinician in ADAPTABLE?

SJ: The role of the clinician in ADAPTABLE is that of support. Patients, especially older patients, like to hear about and discuss participation in clinical trials with their clinicians. We hope that clinicians will be able to answer questions, confirm eligibility, and validate that participating in ADAPTABLE may be of benefit to their patients. We expect that clinicians will be aware of ADAPTABLE and discuss the benefits and attributes of the study:

  • Low-risk study for the participant
  • Answers an important clinical question
  • Defines an effective model for the conduct of clinical research

Watch this video to learn more about the role of clinicians in ADAPTABLE and how clinicians can be ADAPTABLE champions.

Q: What types of challenges do clinicians face in clinical research and how can studies like ADAPTABLE help? Continue reading The Role and Importance of the Clinician in ADAPTABLE

ADAPTABLE: Answering an Important Clinical Question while Testing a New Approach to Conducting Pragmatic Clinical Trials

In April, Ty Rorick and Lisa G Berdan of the ADAPTABLE Coordinating Center at Duke Clinical Research Institute (DCRI) visited the Research Action for Health Network (REACHnet) team. “REACHnet has developed a very clever way of using tablets in some of their clinics to help reach potential participants previously identified using the computable phenotype. They have just enrolled their first ADAPTABLE patient and we’re very excited to see how tablet technology can help engage participants early in the screening process” said Lisa G Berdan, Director, DCRI Global Cardiovascular Outcomes Trials.

In this feature of Ask ADAPTABLE, Beth Nauman, Research Director at REACHnet, shares the network’s role in the National Patient-Centered Clinical Research Network (PCORnet) and ADAPTABLE.

Continue reading ADAPTABLE: Answering an Important Clinical Question while Testing a New Approach to Conducting Pragmatic Clinical Trials

ADAPTABLE Presented to the American College of Cardiology Board of Governors

ADAPTABLE physician leaders Robert Harrington and Matthew Roe along with operations team leaders Lisa Berdan and Tyrus Rorick presented ADAPTABLE to the American College of Cardiology (ACC) Board of Governors (BOG) on April 1, 2016 during the annual ACC scientific sessions. The ACC BOG is the grassroots liaison organization that represents the local state ACC chapters within the ACC headquarters. Their presentation generated a thoughtful discussion about the goals and objectives of ADAPTABLE.  The BOG members expressed uniform support in communicating the importance of ADAPTABLE to local chapter leaders and local ACC state members and constituents to raise awareness of the trial among cardiologists across the United States. The ADAPTABLE team committed to providing the BOG with study updates, to connect local chapter leaders with the leaders of ADAPTABLE at the participating CDRNs and health care systems, and to work together with the BOG to facilitate the widespread dissemination of information about ADAPTABLE to the cardiology community.